EU Biotech Act Explainer
Strengthening Europe's Biotechnology and Biomanufacturing
The Commission's proposal to transform Europe's biotechnology and biomanufacturing sector. Strategic projects, regulatory sandboxes, clinical trial acceleration, biosecurity, and EUR 20.4 billion in funding. Here is everything you need to know.
Europe leads in science but lags in commercialisation
The EU biotechnology industry has grown more than twice as fast as the overall EU economy and accounted for EUR 38.1 billion of Union GDP in 2022. Each job in industrial biotech generates 3.4 additional jobs. Yet the EU captures only 7% of global health biotech VC (vs 63% for the US, 14% for China). US biopharma start-ups receive 9 times more late-stage funding than EU equivalents.
Subject matter, scope, and key definitions
1. Improve the functioning of the internal market by strengthening the competitiveness of the health biotech sector, from research to production.
2. Create conditions for the development and timely placing on the EU market of biotech innovations, products, and services.
3. Safeguard high standards for human and animal health, environment, ethics, quality, food and feed safety, and biosecurity.
Biotechnology: the application of science and technology to living organisms, their parts, products, or models, to alter living or non-living materials for the production of knowledge, goods, and services.
Health biotechnology: the application of biotechnology in the human medical, veterinary, pharmaceutical, and phytosanitary areas for the development of biotechnology products and services.
Scope: covers the entire lifecycle: research, access to funding, development, innovation, testing, validation, manufacturing, placing on the market, and use.
Pillar 1: recognising and supporting biotechnology strategic projects
The Act creates a framework for recognising health biotechnology strategic projects at Member State level and high-impact health biotechnology strategic projects at EU level. Both receive accelerated permitting, priority administrative support, and "highest national significance" designation under national law.
Pillar 2: EU health biotechnology investment pilot
Partnership: the Commission will establish an EU health biotechnology investment pilot with the European Investment Bank Group and other implementing partners.
Instruments: equity instruments and venture-style debt tailored to biotechnology-specific risk profiles, targeting the Series B, C, and growth-stage funding gap.
Capital Booster Pilot: projects contributing to a late-stage capital booster may be recognised as high-impact strategic projects.
State aid: all funding measures must comply with applicable State aid rules.
Extending supplementary protection certificates for biotech products
12-month extension of the Supplementary Protection Certificate (SPC) for medicinal products developed by means of biotechnology processes and for Advanced Therapy Medicinal Products (ATMPs).
Rationale: incentivise the development of products using innovative biotechnology technologies that bring a therapeutic advantage to patients.
Conditions: subject to compliance with applicable competition rules.
Pillar 3: enhancing EU competitiveness in biosimilars
EMA guidelines to facilitate the authorisation of biosimilar medicinal products.
Strategic projects focused on biosimilar research, development, manufacturing, and marketing authorisation.
International cooperation for biosimilar clusters between economic operators and biotechnology clusters.
Context: biological medicines represent 41% of EU pharmaceutical spending. Biosimilars are critical for affordability and access.
Pillar 4: integrating artificial intelligence and data into biotechnology
Pillar 5: regulatory tools for products outside existing frameworks
Regulatory status repository: Union-wide, cross-framework repository compiling opinions, recommendations, decisions, and guidance on novel biotech product classification.
Foresight Panel for Emerging Health Innovation: horizon-scanning and cross-framework dialogue on forthcoming scientific and technological developments.
Regulatory sandboxes: Union-level sandbox for health biotech products at an early stage of development that fall outside existing health legal frameworks.
Pillar 6: preventing the misuse of biotechnology
Economic operators and online marketplaces must report suspicious transactions involving "biotechnology products of concern" to national contact points within 24 hours. Red flags include: unclear customer identity, orders inconsistent with normal business practices, unusual labelling or shipping requests, and deliveries to addresses lacking legitimate biotech justification.
EU biodefence capability projects eligible for high-impact strategic project status.
Linked to the EU Dual Use Regulation (2021/821) and the Preparedness Union Strategy.
Screening: provisions for screening, reporting, and tracking biotechnology products of concern, with enforcement mechanisms to ensure compliance.
Pillar 7: amending 6 existing EU regulations to reduce time-to-market
Multinational trial authorisation: 106 days reduced to 75 days (including validation and ethical review).
Initial authorisation (no info request): 75 days reduced to 47 days.
Substantial modification: 96 days reduced to 47 days (with parallel options).
ATMP extra time: additional 50-day assessment period eliminated.
New features: "minimal-intervention clinical trials" category, mandatory EU harmonised templates, single core dossier, clinical trial sandboxes, AI uptake fostered.
Monitoring, evaluation, delegation, and entry into force
Monitoring: continuous evidence base through regularly updated strategic mapping and project lists.
Evaluation: 5 years after entry into application, then every 5 years. Report to EP, Council, EESC, and CoR.
Delegation: Commission empowered to adopt delegated acts for technical updates.
Entry into force: 20 days after publication in the Official Journal.
Confidential information: provisions on handling sensitive business and security data.
Key changes introduced by the proposal
| Aspect | Current situation | With the Biotech Act |
|---|---|---|
| Multinational clinical trial authorisation | 106 days | 75 days |
| Initial clinical trial (no info request) | 75 days | 47 days |
| Substantial modification assessment | 96 days | 47 days |
| ATMP extra assessment time | 50 additional days | Eliminated |
| Study notification delay (food law) | 6 months | 3 months |
| Biotech strategic project recognition | No framework | 10 months (MS) / 8 months (EU) |
| Regulatory sandboxes for biotech | None at EU level | 5 types (health, clinical, food, vet, SoHO) |
| Biosecurity reporting | Fragmented national rules | 24-hour mandatory reporting |
| Late-stage biotech funding | 7% of global VC | EIB investment pilot + Capital Booster |
| SPC for biotech products | Standard duration | +12 months for biotech processes and ATMPs |
| AI guidance for medicines | Ad hoc | Systematic EMA guidance + sandbox |
| GMO assessment (vet products) | Dual assessment (ERA + GMO) | ERA only (duplicate removed) |
How Europe compares to the US and China in biotechnology
| Metric | EU | USA | China |
|---|---|---|---|
| Top 10% publications (biology, biomedical) | 21% | 22% | 24% |
| Share of global health biotech VC (2015-2025) | 7% | 63% | 14% |
| Health biotech VC volume (2015-2025) | EUR 25B | EUR 219B | n/a |
| Clinical trial authorisation time | 113 days | ~60 days | ~60 days |
| Share of commercially sponsored trials | 12% | Stable | 18% |
| Biotech IPOs on local exchanges (6 years) | 1 | 66 | n/a |
In Parliament the Act is steered by a joint committee of Public Health (SANT) and Industry, Research and Energy (ITRE)
Because the Biotech Act sits across both health policy and industrial competitiveness, the European Parliament referred it to a joint SANT-ITRE committee (internal code CJ53) under Rule 58 of its Rules of Procedure. The two committees take the file together, with a single shared set of shadow rapporteurs. Committee referral was announced in plenary on 18 May 2026, and the procedure is currently awaiting the joint committee's draft report. Legal basis: Articles 114, 168(4) and 173(3) TFEU, plus Rule 58.
EPP: Ingeborg Ter Laak
S&D: Dario Nardella
Patriots for Europe (PfE): Margarita de la Pisa Carrión (also the author of the SANT precursor report below)
ECR: Kristoffer Storm, Carlo Ciccioli
Renew Europe: Katri Kulmuni, Stine Bosse
Greens/EFA: Marie Toussaint, Ville Niinistö
The Left: Anja Hazekamp, Anthony Smith
ESN: Christine Anderson
ECON, IMCO, LIBE and BUDG were asked to contribute an opinion but declined, leaving ENVI and JURI as the only opinion-giving committees.
Before the Commission tabled the Act, the EP set out its expectations in two own-initiative reports, one industrial (ITRE), one health (SANT)
This own-initiative report is Parliament's industrial case for the Act. It frames biotechnology and biomanufacturing as one of ten strategic technology sectors for Europe's competitiveness, anchored in the Draghi competitiveness report and the Competitiveness Compass. Its headline demands: the Act should be justified by concrete regulatory gaps and accompanied by an impact and cost assessment plus a Regulatory Scrutiny Board review, under the "one in, one out" simplification principle; a single coordination body, a "Chief Biotechnology Officer", inside the Commission; a "biotechnology omnibus" simplifying requirements across frameworks; streamlined, science-based authorisation procedures (flagging the EFSA and ECHA reviews); a common clinical-trials framework using real-world evidence and harmonised, internationally competitive intellectual-property rules; and the next generation of regulatory sandboxes. It adds a cluster of horizontal asks: feedstock and supply-chain security, academia-to-industry technology transfer, lower energy prices, a skilled workforce, completion of the capital markets union, a strengthened InvestEU and a dedicated SME funding initiative, doubling the EU research budget toward 3% of GDP on R&D, and integrating biotech into the EU digital and AI strategies.
Own-initiative report 2025/2008(INI), rapporteur Hildegard Bentele (EPP). Committee vote 25 June 2025; adopted in plenary 10 July 2025 (report A10-0123/2025, resolution T10-0165/2025). Procedure completed.
This own-initiative report is Parliament's health-and-ethics view. It first catalogues biotech's clinical promise (CAR-T, mRNA, CRISPR and ATMPs; molecular diagnostics, multi-omics, regenerative medicine) and then sets the guardrails. Its headline demands: the Biotech Act should simplify the regulatory framework while preserving high safety standards, supported by an EU biotech hub and next-generation sandboxes; sector-specific Commission guidelines for AI in diagnosis and treatment; stronger technology transfer, traceability of research outcomes, intellectual-property protection and tailored support for biotech SMEs, which make up the bulk of the sector; more public and private early-stage investment (welcoming STEP but noting that EU funding lags competitors), affordability of therapies, and action on brain drain. Its centre of gravity is ethics: a precautionary yet innovation-enabling approach, strong ethical oversight, no trait-selection or eugenic attitudes toward persons with disabilities, cooperation among independent national ethics committees with respect for Member State competence, an explicit welcome for the ban on germline modification, alignment with the UNESCO Universal Declaration on the Human Genome and Human Rights, and stronger protection of health and genetic data including human oversight of AI. It calls for an impact assessment before publication and a technology-neutral approach.
Own-initiative report 2025/2087(INI), rapporteur Margarita de la Pisa Carrión (PfE). Committee vote 2 December 2025, report tabled for plenary 19 December 2025 (A10-0274/2025); awaiting the plenary vote.
The Commission's Act largely delivers the ITRE report's competitiveness agenda, but in a narrower, health-only form, and it under-delivers on the SANT report's ethics agenda. The two committees converge with the Commission on regulatory sandboxes, faster clinical-trial authorisation, cross-framework simplification, fast-track permitting for strategic projects, AI as an enabler and a dedicated funding pilot. They diverge on scope (the Act covers health biotech only, with a "Biotech Act II" promised for agriculture, industry and energy), on governance (Parliament wanted a single Chief Biotechnology Officer, the Act creates a Steering Group and Support Network instead), and most sharply on bioethics, where the SANT report's safeguards are largely absent from the operative articles of an Act built around competitiveness, funding and biosecurity. With SANT's own report author, Margarita de la Pisa Carrión, now sitting as a shadow on the legislative file, that ethics gap is a likely flashpoint in the joint-committee negotiation.
| What Parliament asked for | What the Commission's Act does |
|---|---|
| Regulatory sandboxes for biotech | Delivered: five sandbox types |
| Faster clinical-trial authorisation | Delivered: 106 to 75 days, ATMP extra delay removed |
| Simplify across frameworks (an "omnibus") | Partly: six regulations amended |
| Harmonised, competitive IP and patents | Partly: +12-month SPC for biotech processes and ATMPs |
| Close the late-stage funding gap | Delivered: EIB investment pilot + Capital Booster |
| A single "Chief Biotechnology Officer" | Not delivered: Steering Group + Support Network instead |
| Broad scope (industrial, agri, energy biotech) | Health biotech only (Biotech Act II promised) |
| Strong bioethics safeguards (germline ban, anti-eugenics, ethics committees, genetic data) | Largely absent from the Act's articles |
| Impact assessment and RSB review | Partly: SWD analytical document accompanies the proposal |
The Commission presented the proposal to the joint SANT-ITRE committee
On Wednesday 19 March 2026, 11:00 to 12:30, the joint SANT-ITRE committee (meeting reference CJ53(2026)0319_1) held its first consideration of the European Biotech Act. Item 3 on the agenda was the Commission's presentation of the proposal (COM(2025) 1022, parliamentary reference C10-0363/2025). At this stage only the Commission proposal was on the table: no draft report and no amendments had yet been tabled, confirming that the file is still in its preparatory phase in Parliament.
From political guidelines to application
All documents used to produce this analysis
Proposal (Regulation): COM(2025) 1022 final (PDF)
Companion Directive: COM(2025) 1031 (genetically modified micro-organisms and organ processing)
Analytical document: SWD(2025) 1055 final
Official page: DG SANTE: Biotechnology
Independent analysis: eu-biotech-act.com (Cyber Risk GmbH regulatory analysis)
Background: COM(2024) 137 "Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU"
Life sciences strategy: COM(2025) 525 "Choose Europe for life sciences"
Legislative procedure file: OEIL 2025/0406(COD) (joint SANT-ITRE committee, rapporteurs, shadows, key events)
ITRE precursor report: 2025/2008(INI) "Future of the EU biotechnology and biomanufacturing sector" (rapporteur Hildegard Bentele, adopted 10 July 2025)
SANT precursor report: 2025/2087(INI) "Public health aspects of biotechnology and life sciences" (rapporteur Margarita de la Pisa Carrión, committee vote 2 December 2025)